看了一篇文献，似乎已经证明了替诺对母乳的孩子没有影响

familyjiankang

对50组吃替诺的并哺乳的母亲和孩子进行研究，母亲的母乳中替诺的浓度只有血液浓度的3%，另外是94%的婴儿的血液中的替诺都是不可测量的！
另外求大神指点：“ Based on the milk concentration, the infants had TFV exposures at less than 0.01% of the proposed infant therapeutic dose (6 mg/kg)”这句话应该怎么翻译啊？
求大神找一下这篇文章的文献原文呢！
感谢啊，一位纠结的替诺待产妈妈们！
以下是我搜的文章原文：
TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Simon Collins, HIV i-Base

A study reporting that low TDF/FTC concentrations in breastmilk do not put a baby at risk will be important in enabling women to routinely use PrEP irrespective of whether or not they are breastfeeding.

Kenneth Mugwanya from University of Washington presented results from a pharmacokinetic study in 50 mother and infant pairs. The mothers were given daily PrEP for ten days with drugs levels measured in both breast milk samples and infant plasma samples. [1]

Median age of the infants was 13 weeks.

Only very small quantities of tenofovir (median med 0.2 ng/mL) transferred to milk – approximately at 3% of blood levels in the mothers. Tenofovir was not quantifiable in 94% of infant plasma samples. Based on the milk concentration, the infants had TFV exposures at less than 0.01% of the proposed infant therapeutic dose (6 mg/kg).

Emtricitabine (FTC) concentrations in breast milk were also low, although somewhat higher (median 212.5 ng/mL). These concentrations were consistent with those seen with 3TC, abacavir and AZT. Overall, 47/49 samples had detectable FTC in infant plasma, but at small concentrations (13.2 ng/mL), equivalent to approximately 0.5% of the proposed therapeutic infant dose.

Even though this was a small study, it provides the first data to suggest that PrEP can be safely used by women who are breastfeeding.

Full results from the study were published as an open access paper in PLoS Medicine in September 2016. [2]